Dishman Carbogen Amcis working capital

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
856.88×856.88×648.70×515.45×517.06×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
83.29×83.29×75.80×73.33×80.42×
197.26×197.26×172.73×141.75×147.42×
742.91×742.91×551.77×447.03×450.06×
5.53×5.58×9.84×−4.18×20.11×
0.27×0.27×0.28×0.27×0.27×
5.04×5.04×115.81×−2.50×−7.39×
0.87×0.87×0.80×1.34×0.66×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DCAL₹149.42

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,343 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)517.06515.45648.70856.88856.88
Receivable Days (DSO)80.4273.3375.8083.2983.29
Payable Days (DPO)147.42141.75172.73197.26197.26
Cash Conversion Cycle (days)450.06447.03551.77742.91742.91
Working Capital Turnover20.11-4.189.845.585.53
Asset Turnover0.270.270.280.270.27
Cash Conversion (CFO/Net Income)-7.39-2.50115.815.045.04
CFO/EBITDA0.661.340.800.870.87
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.